| Identification | Back Directory | [Name]
PAOPA | [CAS]
114200-31-6 | [Synonyms]
PAOPA
(3R)-2-Oxo-3-[[(2S)-2-Pyrrolidinylcarbonyl]amino]-1-pyrrolidineacetamide
PAOPA (S)-N-((R)-1-(2-amino-2-oxoethyl)-2-oxopyrrolidin-3-yl)pyrrolidine-2-carboxamide | [Molecular Formula]
C11H18N4O3 | [MDL Number]
MFCD27991290 | [MOL File]
114200-31-6.mol | [Molecular Weight]
254.29 |
| Chemical Properties | Back Directory | [Boiling point ]
647.6±55.0 °C(Predicted) | [density ]
1.33±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in water and to 100 mM in DMSO | [form ]
Powder | [pka]
14.21±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PAOPA is an allosteric modulator and a potent dopamine D2 receptor. It is used to treat psychiatric illnesses, such as schizophrenia. | [Definition]
ChEBI: (2S)-N-[(3R)-1-(2-amino-2-oxoethyl)-2-oxo-3-pyrrolidinyl]-2-pyrrolidinecarboxamide is a peptide. | [in vivo]
Chronic administration of PAOPA (1 mg/kg; ip; once a day for 45 days) causes an increase in the expression of D2 receptor regulators and downstream molecules (including GRK2, arrestin-3, and extracellular receptor kinase ERK 1/2) in mice[1]. | [IC 50]
D2 Receptor | [storage]
Store at -20°C |
|
|